TY - JOUR
T1 - Current status of thalidomide and its role in the treatment of metastatic prostate cancer
AU - Macpherson, Gordon R.
AU - Franks, Michael
AU - Tomoaia-Cotisel, Andrada
AU - Ando, Yuichi
AU - Price, Douglas K.
AU - Figg, William D.
PY - 2003/6/27
Y1 - 2003/6/27
N2 - Following the discovery of its anti-angiogenic properties and despite its tragic history, thalidomide has re-surfaced in the field of oncology. Concurrent with its evaluation in various clinical trials for cancer, thalidomide's mechanism of action is sought and new analogues with improved efficacy and pharmacological profile are emerging. This review is a critical evaluation of thalidomide metabolism, molecular targets, anti-angiogenic activity and clinical efficacy with an emphasis on metastatic prostate cancer.
AB - Following the discovery of its anti-angiogenic properties and despite its tragic history, thalidomide has re-surfaced in the field of oncology. Concurrent with its evaluation in various clinical trials for cancer, thalidomide's mechanism of action is sought and new analogues with improved efficacy and pharmacological profile are emerging. This review is a critical evaluation of thalidomide metabolism, molecular targets, anti-angiogenic activity and clinical efficacy with an emphasis on metastatic prostate cancer.
KW - Prostate
KW - Prostate cancer
KW - Thalidomide
UR - http://www.scopus.com/inward/record.url?scp=0038692961&partnerID=8YFLogxK
U2 - 10.1016/S1040-8428(03)00064-7
DO - 10.1016/S1040-8428(03)00064-7
M3 - Article
C2 - 12850527
AN - SCOPUS:0038692961
SN - 1040-8428
VL - 46
SP - 49
EP - 57
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - SUPPL.
ER -